Focus on Diversity Boosts Number of Women Speakers at ISC – TCTMD

LOS ANGELES, CAA concerted effort by the American Heart Association/American Stroke Association (AHA/ASA) and the program planning committee of the International Stroke Conference (ISC) successfully increased the number of women who were invited as speakers at the 2019 meeting, a new study shows.

Between 2014 and 2018, only 28% of invited speakers at the annual stroke meeting were women, but that number jumped to 47% in 2019, Anjail Sharrief, MD (McGovern Medical School at UTHealth, Houston, TX), reported at the ISC here last week.

A particularly large gain in the proportion of women was seen among physician speakersincreasing from 17.7% in 2014-2018 to 37.9% in 2019.

Its important for . . . the [meeting] committees to acknowledge the disparities and enhance focus on diversity among speakers, and this influences change, Sharrief, director of stroke prevention for the UTHealth Institute of Stroke and Cerebrovascular Disease, said during her presentation. Increased opportunities to speak at major scientific conferences for women may help to address factors that contribute to gender differences in academic advancement and promotion.

She noted, however, that more work must be done to increase speaker diversity by race and country, and across different presentation categories.

Women Underrepresented in Multiple Areas

Its known that at the faculty level in neurology, men exceed women in terms of academic positions, rank, and number of publications. The proportion of women is highest among assistant professors (47%), falling to 38% among associate professors and 21% among full professors, according to Sharrief.

Speaker lineups at meetings are also male-dominated, she pointed out. As reported at ISC 2019 by Sharriefs colleague Lauren Fournier, MD (McGovern Medical School at UTHealth), women made up only about one-quarter of invited speakers in the prior 5 years of the meeting despite representing 37.7% of all attendees, with no changes over that span. Representation was particularly problematic when it came to physician speakers and women from racial/ethnic minority groups.

Its important to have different perspectives and different lenses through which we look. Anjail Sharrief

The ISC program planning committee encouraged Sharriefs team to look into the issue, and between 2018 and 2019, put a focus on increasing diversity among speakers and recruiting more qualified women to present. At the 2019 meeting, ISC included a mentoring lunch for women and a special event around womens issues in stroke, and at this years meeting, there were even more programming activities around womens issues, Sharrief said.

To find out if those efforts had an impact, Sharrief and her colleagues obtained data from the American Heart Association/American Stroke Association on invited speakers who presented at the 2019 meeting.

The gains in the proportion of women speakers from 2014-2018 to 2019 seemed to be evident across various academic-degree categories, although numbers were small for certain categories.

Women were more likely to be invited for debate in 2019 than in the prior 5 years (37.5% vs 13.1%) and to be invited to speak in the acute, in-hospital care category (39.8% vs 19.0%). Of the speakers who presented more than once in 2019, 46% were women, an improvement over the 21.3% rate seen in prior years.

Increases in the proportion of women were also seen across racial/ethnic categories, with substantial jumps among whites (32.7% to 48.2%) and Asians (20.0% to 41.2%). There were apparent improvements among Hispanic and African-American women as well, although overall numbers of speakers from these groups remained small.

Geographically, female representation was improved among speakers from North America and Europe, but speakers from other parts of the world remained less common. There were no female speakers from Africa.

I think theres still work to do in terms of further diversity, Sharrief told TCTMD.

Importance of More-Diverse Speakers

Sharrief said that having a more diverse lineup of speakers at major medical meetings is important for a number of reasons. For one, it makes for better science, because there are issues in stroke that differentially affect women and people from racial/ethnic minority groups. Its important to have different perspectives and different lenses through which we look, Sharrief said. So by having a diversity of speakers presenting you really are looking things from different perspectives.

Then, on a professional level, data presented by Sharriefs colleague, Pamela Zelnick, MD (McGovern Medical School at UTHealth), showed that even women account for half of medical students, they remain less likely than men to go into neurology or vascular neurology. If we want to continue to attract the brightest and the best students and residents, then we have to show that there are opportunities for them in leadership, and having opportunities to speak at conferences gives people opportunities for leadership within the organization but also for academic advancement, Sharrief said.

To that last point, she noted that contributions to science and recognitions of achievement are important when it comes to being promoted. Being invited to conferences [is something] that you can list there as being evidence of peer esteem, evidence that you have had an impact on a national/international level, Sharrief said.

Thus, its important to continue to track diversity among speakers and report the findings, and ensure that the leaders of the AHA/ASA and ISC maintain their focus on the issue every year so the gains are not lost, Sharrief said, adding that it seems they are committed to doing so.

Bruce Ovbiagele, MD (University of California, San Francisco), a co-author on Sharriefs study and ISC program committee chair in 2017 and 2018, told TCTMD that its gratifying to see that in such a short period of time things seem to have improvedmaybe because were highlighting it morebut it would be nice to have a systematic way of making sure that is always the case and a way of obviously measuring later on to see if the effect is actually sustained.

The key to ensuring a lasting effect is the attention factor, he said, noting that Louise McCullough, MD, PhD (McGovern Medical School at UTHealth), who was vice chair of ISC 2019 and 2020 and will be chair of the meeting for the next 2 years, has a number of strategies she wants to incorporate. One, for example, is making sure each invited speaker panel has at least one woman. He noted that inviting more women is one thing, but ensuring that the speakers who actually attend the meeting are more diverse is another. McCullough, he said, has promised to intensify efforts to replace women who decline invitations with other women whenever possible.

The ASA is definitely doing a lot to make sure that there are more womanels and not manels, Ovbiagele said.

What Sharrief takes away from this look into representation of women at the ISC is that change can happen if we think to look and see where the differences are. Diversity is important for many reasons.

See the article here:
Focus on Diversity Boosts Number of Women Speakers at ISC - TCTMD

Association of Clusterin Levels in Cerebrospinal Fluid with Synaptic D | NDT – Dove Medical Press

Jun Wang,* Xin Zhang,* Bihong Zhu, Pan Fu On the behalf of Alzheimers Disease Neuroimaging Initiative

Department of Neurology, Taizhou First Peoples Hospital, Zhejiang, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Pan FuDepartment of Neurology, Taizhou First Peoples Hospital, 218 Hengjie Road, Huangyan District, Taizhou City, Zhejiang Province, Peoples Republic of ChinaEmail fp7154515@163.com

Purpose: Although emerging evidence has suggested that clusterin is involved in the pathogenesis of Alzheimers disease (AD), the association of clusterin with synaptic degeneration in living human is unclear. In the present study, we aimed to examine the association of CSF clusterin levels with synaptic degeneration in individuals with different severities of cognitive impairment.Patients and Methods: In the present study, we compared levels of clusterin in CSF among individuals with normal cognition (NC), mild cognitive impairment (MCI), and AD. Further, linear regression models were performed to examine the association of CSF clusterin with neurogranin (NG, reflecting synaptic degeneration) with adjustment of several potential confounders.Results: We found that CSF clusterin levels were positively correlated with NG in the NC and MCI groups, but not the AD group. In all subjects, linear regression models suggested that clusterin levels were positively associated with NG levels independent of age, gender, apolipoprotein E4 (APOE4) genotype, clinical diagnosis, and CSF A 42 levels.Conclusion: Our data indicated that clusterin was associated with CSF NG levels among older individuals with different severities of cognitive impairment.

Keywords: clusterin, neurogranin, synaptic degeneration, Alzheimers disease, mild cognitive impairment

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the article here:
Association of Clusterin Levels in Cerebrospinal Fluid with Synaptic D | NDT - Dove Medical Press

Interventional Neurology Professional Inspection Report and Forecast 2020-2026 Dagoretti News – Dagoretti News

Global Interventional Neurology MarketIndustry Analysts 2020. The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Interventional Neurology market. The report offers an overview of the market, which briefly describes the market condition and the leading segments. It also mentions the top players present in the global Interventional Neurology market. The research report on the global Interventional Neurology market includes a SWOT analysis and Porters five forces analysis, which help in providing the precise trajectory of the market.

Get Free Sample Copy of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/56

Points Covered in The Report:

The points that are discussed within the report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. The historical data from 2012 to 2017 and forecast data from 2019 to 2026.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by manufacturer, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

The Interventional Neurology Market report incorporates analysis of new advancements in innovation, detailed profiles of fundamental industry players, and outstanding model investigation. It provides a market forecast for the forthcoming years. The report covers up the evaluation of macro and micro features vital for the already established Interventional Neurology market players and the newly emerging players in various regions all across the world.

Major Players in the Interventional Neurology Market:Medtronic, Inc. (Covidien), Penumbra, Inc., Stryker Corporation, Johnson & Johnson and Terumo Corporation

Get Free PDF Brochure of This Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/56

Interventional Neurology Market: Regional Overview

Geographically, the Interventional Neurology market is segmented into seven regions, namely North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). The growth of the Asia-Pacific market is supposed to be comparatively high as compared to other regions across the globe due to increasing inclination of consumers towards convenient in the regions. Interventional Neurology Market in the fast-developing nations such as China and India are estimated to witness robust revenue growth and trend to continue over the forecast period. Production of polymers such as polyethylene and polyethylene terephthalate used in manufacturing in flexible pouches is highest in North America and Europe region.

Reasons for Buying Interventional Neurology market

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

(Exclusive discount on this report) https://www.coherentmarketinsights.com/insight/request-discount/56

About us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Raj Shah

Phone: US +12067016702 / UK +4402081334027

Email:[emailprotected]

Visit our Blog:https://hospitalhealthcareblog.wordpress.com/

Go here to read the rest:
Interventional Neurology Professional Inspection Report and Forecast 2020-2026 Dagoretti News - Dagoretti News

Global Gene Therapy Market is Projected to Reach USD 13.0 Billion by 2024 from USD 3.8 Billion in 2019, at a CAGR of 27.8% – ResearchAndMarkets.com -…

The "Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

High incidence of cancer & other target diseases is a major factor driving the growth of the gene therapy market

The high incidence of cancer and other target diseases, availability of reimbursement, and the launch of new products are the major factors driving the growth of this market. In addition, the strong product pipeline of market players is expected to offer significant growth opportunities in the coming years. However, the high cost of treatment is expected to hamper the market growth to a certain extent in the coming years.

Neurological diseases segment accounted for the largest share of the gene therapy market, by indication, in 2018

Based on indication, the market is segmented into neurological diseases, cancer, hepatological diseases, Duchenne muscular dystrophy, and other indications. The neurological diseases segment accounted for the largest share of the market in 2018. This can be attributed to the increasing number of gene therapy products being approved for the treatment of neurological diseases and the high market penetration of oligonucleotide-based gene therapies.

Viral vectors segment to register the highest growth in the gene therapy market during the forecast period

The gene therapy market, by vector, has been segmented into viral and non-viral vectors. In 2018, the non-viral vectors segment accounted for the largest share of this market. However, the viral vectors segment is estimated to grow at the highest CAGR during the forecast period, primarily due to the increasing demand for CAR T-based gene therapies and the rising incidence of cancer.

North America will continue to dominate the gene therapy market during the forecast period

Geographically, the market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the gene therapy market, followed by Europe. Factors such as the rising prevalence of chronic diseases, high healthcare expenditure, presence of advanced healthcare infrastructure, favorable reimbursement scenario, and the presence of major market players in the region are driving market growth in North America.

Key Benefits of Buying the Report:

This report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. Also, this report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.

Key Topics Covered:

1 Introduction

1.1 Objectives of the Study

1.2 Market Definition

1.3 Market Scope

1.4 Currency

1.5 Limitation

1.6 Stakeholders

2 Research Methodology

2.1 Research Data

2.2 Secondary Data

2.3 Primary Data

2.4 Market Size Estimation

2.5 Market Breakdown and Data Triangulation

2.6 Assumptions for the Study

3 Executive Summary

4 Premium Insights

4.1 Gene Therapy Market Overview

4.2 North America: Market, By Vector (2018)

4.3 Geographical Snapshot of the Market

5 Market Overview

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers

5.2.1.1 High Incidence of Cancer and Other Target Diseases

5.2.1.2 Product Approvals

5.2.1.3 Funding for Gene Therapy Research

5.2.2 Opportunities

5.2.2.1 Strong Product Pipeline

5.2.3 Challenges

5.2.3.1 High Cost of Treatments

6 Gene Therapy Market, By Vector

6.1 Introduction

6.2 Non-Viral Vectors

6.3 Viral Vectors

7 Gene Therapy Market, By Indication

7.1 Introduction

7.2 Neurological Diseases

7.3 Cancer

7.4 Hepatological Diseases

7.5 Duchenne Muscular Dystrophy

7.6 Other Indications

8 Gene Therapy Market, By Delivery Method

8.1 Introduction

8.2 In Vivo Gene Therapy

8.3 Ex Vivo Gene Therapy

9 Gene Therapy Market, By Region

9.1 Introduction

9.2 North America

9.3 Europe

9.4 Asia Pacific

9.5 Rest of the World

Story continues

10 Competitive Landscape

10.1 Overview

10.2 Market Share Analysis, 2018

10.3 Key Strategies

10.4 Competitive Leadership Mapping (2018)

10.4.1 Visionary Leaders

10.4.2 Innovators

10.4.3 Dynamic Differentiators

10.4.4 Emerging Companies

11 Company Profiles

11.1 Biogen

11.2 Gilead Sciences, Inc.

11.3 Amgen, Inc.

11.4 Novartis AG

11.5 Orchard Therapeutics Plc

11.6 Spark Therapeutics, Inc. (A Part of Hoffmann-La Roche)

11.7 Molmed S.P.A.

11.8 Anges, Inc.

11.9 Bluebird Bio, Inc.

11.10 Human Stem Cells Institute (HSCI)

11.11 SIBIONO Genetech Co., Ltd.

11.12 Shanghai Sunway Biotech Co., Ltd

11.13 Uniqure N.V.

11.14 Gensight Biologics S.A.

11.15 Celgene Corporation (A Bristol-Myers Squibb Company)

11.16 Cellectis

11.17 Sangamo Therapeutics

11.18 Mustang Bio

11.19 AGTC (Applied Genetic Technologies Corporation)

11.20 Poseida Therapeutics, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/xhxwrm

View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005314/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See the original post:
Global Gene Therapy Market is Projected to Reach USD 13.0 Billion by 2024 from USD 3.8 Billion in 2019, at a CAGR of 27.8% - ResearchAndMarkets.com -...

Should aspirin be given to all stroke victims? – Quartz

First sold commercially 119 years ago, aspirin is a remarkable drug. Cheap and with few side effects, its benefits include the ability to prevent blood cells from clotting. As a result, its given to patients who have suffered heart attacks, which are caused by clots blocking arteries leading to the heart.

Aspirin can also help prevent strokesspecifically ischemic strokes, the most common kind, which are caused by clots that block the flow of blood in the brain. Giving ischemic stroke victims aspirin can reduce the chances of a second stroke after two to four weeks by about 12%, and by about 17% over the next three years.

But not all stroke patients receive aspirin. For hemorrhagic strokesthe other main form of stroke, cause by a ruptured blood vessel in the brainpatients need their blood to clot to stop uncontrolled bleeding. So doctors never give aspirin to hemorrhagic patients out of fear of causing another stroke.

For decades, if the type of stroke is unknown, standard practice has been to deny aspirin to prevent unintended harm to hemorrhagic stroke victims. CT scans are necessary to make the right diagnosis and guide the course of treatmentbut they are often unavailable in rural hospitals and clinics across the developing world. Thats one reason fewer than 4% of stroke patients in low-income countries are on anti-platelet therapies like aspirin, compared to more than half in high-income countries.

Aaron Berkowitz, a neurologist specializing in treating stroke in poor countries, wants to turn that conventional wisdom on its head. In a 2014 paper, he argued the harm caused by giving aspirin to hemorrhagic stroke patients is overstated, and that it make sense to give aspirin to all stroke victims when the type of stroke is unknown.

Berkowitz started with data from pair of massive studies in the 1990s that looked at the effect of aspirin on a total of 40,000 stroke patients. While those studies were designed for ischemic stroke victims, 773 hemorrhagic victims were inadvertently included, enough to provide a baseline understanding of how those patients respond to aspirin.

He then ran computer simulations that modeled the impact of aspirin treatment on a large population of stroke patients when the type of stroke was unknown. In the model, Berkowitz dialed the percentage of hemorrhagic strokes up to 34%, the highest known rate in the world, found in sub-Saharan Africa (in the US, its more like 15%).

The results showed that, on balance, giving aspirin to stroke patients reduced a secondary stroke by about eight per 1,000 victims, and reduce deaths by about four per 1,000. While the numbers are small, Berkowitz says, they are statistically significant enough to reconsider how stroke treatment is approached in resource-poor settings.

Stroke is the second-leading killer globally, claiming 5.8 million lives a year, and is both more common and more fatal in low-income countries. Even if aspirin offers only slight improvements in patient outcomes, prescribing it widely could mean saving hundreds of thousands of lives over decades.

Unless there is reason to suspect a hemorrhagic stroke, such as a prior history, Berkowitz recommends giving aspirin after 24 hours when the type of stroke is unknown, even though professional medical associations recommend against it.

The American Heart Association and American Stroke Association guidelines for treating stroke are very useful, he says. There are 100 pages for ischemic stroke and 100 pages for hemorrhagic stroke, but for most countries and for most patients in the world, you wont know what guidelines to open.

Until recently, Berkowitz headed the global neurology program at the Harvard-affiliated Brigham and Womens Hospital, and spent time treating stroke patients in Haiti. He acknowledges theres a difference between prescribing a treatment for patients at the population level and on an individual basis. While it may make sense to give aspirin to hundreds of stroke patients, giving it to the wrong patient, and seeing them suffer the consequences, can be difficult for a doctor. Medicine is this constant tension between what you know is globally correct, and tailoring that to an individual patient, he said.

There is no clear ethical choice, says Christine Mitchell, the director for the center of bioethics at Harvard Medical School. If you took a direct, utilitarian approach, its pretty clear from an aggregate public health perspective, if you can save more lives then you should give aspirin, she said.

But, according to a duty-based framework (also called deontological reasoning), a doctors ethical responsibility is to the patient in front of him or her, not to a theoretical aggregation of patients.

According to that reasoning, you have a duty not to add to the harm of these patients, she said. If theres substantial identifiable risk in advance, if you know a percentage of your patients will have had hemorrhagic strokes, you should not give them aspirin.

While the actual risk of giving aspirin to hemorrhagic patient is unclearthe large 1990s trials suggest there was no adverse affect, and more recent trials suggests it may actually benefit patientsmost doctors are taught its harmful. Changing the course of global treatment is a slow process that could take decades, even if they are endorsed by groups such as the Geneva-based World Health Organization. People can sit in Geneva and write guidelines and put them online, but a lot of people will never know they exist, Berkowitz says.

The challenge is clear in Zambia, a fairly typical low-income country with high rates of stroke. Deanna Saylor, an assistant professor at Johns Hopkins who leads a neurology training program in Lusaka, started giving aspirin to patients with unknown types of stroke in the last year. While they havent formally studied the results, she believes the current research justifies the new protocol. However, when she presented the evidence at a national stroke conference for Zambian physicians there was a lot of dismay and reticence about this recommendation, as it is so counter-intuitive and against what we learned in medical school, she said in an email.

Ultimately, she said, what is needed is a randomized, controlled trial in a setting like Zambia. Until then, a simple, effective drug that can prevent the recurrence of stroke may be overlooked.

Continue reading here:
Should aspirin be given to all stroke victims? - Quartz

Largest US Outbreak of Neurologic Disease to Date Uncovered We Need to Watch This Very Closely – SciTechDaily

The Lancet Infectious Diseases recently published the results of an observational study led by researchers on Childrens Hospital Colorado Infectious Disease and Neurology teams, along with counterparts at the Centers for Disease Control and Colorado Department of Public Health and Environment. The study was conducted from March 1 to November 30, 2018, and led to a discovery of the largest outbreak of enterovirus A71 (EV-A71) in the United States.

We need to watch this very closely. Kevin Messacar, MD

Since the 1990s, every 1 to 3 years, EV-A71 has caused large-scale, and sometimes deadly epidemics in the Asia-Pacific region, which has prompted the development of EV-A71 vaccines. In the United States, detections of this virus have been small-scale and sporadic. However, the unique symptoms, unusually high number of cases, and the geographic clustering of children who were observed during this study, indicated an outbreak.

We need to watch this very closely, said Kevin Messacar, MD, pediatric infectious disease physician and researcher at Childrens Hospital Colorado and University of Colorado Anschutz Medical Campus. Enhanced surveillance is needed in order to determine whether this outbreak was an isolated event, or a warning of impending cyclic outbreaks of EV-A71 neurological disease in the U.S.

In addition to highlighting the need to improve enterovirus surveillance, the observational study also helped identify what other medical providers should be looking for. Children with EV-A71 disease were best differentiated from children with other enteroviruses by the neurological findings of myoclonus (quick, involuntary muscle jerks), ataxia (dizziness), weakness and autonomic instability (dysregulation of heart rate, blood pressure and perfusion). Often times these symptoms can be misunderstood or misattributed to other diagnoses especially among young children.

Finally, its important to note that these viruses tend to appear in seasonal waves. If through additional surveillance efforts, the United States continues to see enteroviruses circulating that cause neurological illness, the development of antivirals and vaccines may need to become a priority.

Were it not for Childrens Hospital Colorados ongoing interest and commitment to the study of enteroviruses, this outbreak would probably not have been detected, noted Drs. Carol Glaser and Mike Wilson in a commentary published alongside the Lancet study. The USA has yet to have large-scale epidemics of enteroviruses as are seen in Asia and other countries, but it should take steps to become better prepared.

References:

Clinical characteristics of enterovirus A71 neurological disease during an outbreak in children in Colorado, USA, in 2018: an observational cohort study by Kevin Messacar, MD; Emily Spence-Davizon, MPH; Christina Osborne, MD; Craig Press, MD; Teri L Schreiner, MD; Jan Martin, MD; Ricka Messer, MD; John Maloney, MD; Alexis Burakoff, MD; Meghan Barnes, MSPH; Shannon Rogers, MS; Adriana S Lopez, MPH; Janell Routh, MD; Susan I Gerber, MD; M Steven Oberste, PhD; W Allan Nix, BS; Prof Mark J Abzug, MD; Prof Kenneth L Tyler, MD; Rachel Herlihy, MD and Samuel R Dominguez, MD, 16 December 2019, The Lancet Infectious Diseases.DOI: 10.1016/S1473-3099(19)30632-2

Enteroviruses: the elephants in the room by Carol Glaser and Michael R Wilson, 16 December 2019, The Lancet Infectious Diseases.DOI: 10.1016/S1473-3099(19)30679-6

See more here:
Largest US Outbreak of Neurologic Disease to Date Uncovered We Need to Watch This Very Closely - SciTechDaily

In the News: St. Louis startup co-founded by WashU neurologist raises $6.6M in funding | WashU Fuse – Washington University in St. Louis Newsroom

Dosenbach

A St. Louis-based startup co-founded by a Washington University in St. Louis neurologist has raised a combined $6.6 million in federal grant funding and private investment, reports the St. Louis Business Journal.

NOUS Imaging was co-founded by Nico Dosenbach, a pediatric neurologist at St. Louis Childrens Hospital and assistant professor of neurology and radiology at Washington University School of Medicine.

The startup, which is headquartered in the Cortex Innovation Community, has developed a software, called FIRMM, which monitors patient motion in real-time during MRI scans. According to NOUS, about 20% of MRI scans annually are rendered useless because of patient movement during the procedure. The FIRMM software can minimize the need for repeat scans or anesthesia, which increases patient safety and saves time and money.

The bulk of the financing stems from a $5.6 million Small Business Innovation Research (SBIR) grant recently awarded to the startup by the National Institutes of Health. NOUS also has raised private financing from CICA Inc., a San Diego-based biotechnology and medical technology investment family office.

The company plans to use the funding to hire additional developers and administrative staff.

Read the full article in the St. Louis Business Journal (subscription required).

Read the original post:
In the News: St. Louis startup co-founded by WashU neurologist raises $6.6M in funding | WashU Fuse - Washington University in St. Louis Newsroom

Welcome to the Advanced Center for Neurology and Headache – Magazine of Santa Clarita

At Advanced Center for Neurology and Headache it is our mission to provide our patients with the most advanced medical treatment and expert care. We feature a diversely qualified team of board-certified medical specialists, with expertise in Pain Management, Sports Medicine, Neurology, Plastic and Reconstructive Surgery, Spine Surgery, Podiatry and Internal Medicine. Our teams combined expertise offers patients the benefit of immediate cohesive diagnostics and solutions all in one office. Our medical practitioners are at the forefront of the field and are among the most highly regarded.Yuvraj Grewal, M.D. earned his medical degree at Ross University School of Medicine, Portsmouth, Dominica and completed his internship at United Health Services, Johnson City, New York. He then went on to the University of Arizona, in Tucson where he completed his neurology training as well as served as Chief Resident. He pursued a fellowship subspecializing in Clinical Neurophysiology emphasizing in epilepsy and nerve conditions.He is board certified in Neurology and a member of the American Academy of Neurology and the American Association of Neuromuscular and Electro-diagnostic Medicine.Dr. Grewal is committed to providing high quality medical care to his patients and to determining the best course of treatment based on the individual case. He truly listens to his patients with a compassionate heart and combines the best of evidence based and state-of-the-art medicine to serve each individual patient. To schedule a consultation with Dr. Yuvraj Grewal, please call 661-888-1099 or email: referral@myACNH.com. The office is located at 23861 McBean Parkway, Suite A-4 in Valencia. You can visit online at http://www.myACNH.com.

Original post:
Welcome to the Advanced Center for Neurology and Headache - Magazine of Santa Clarita

The subject of sleep – Eureka Times-Standard

Instructor Barry Evans will teach a course called Sleep Perchance to Dream Tuesday from 1:30 to 3:30 p.m. through Humboldt State Universitys Osher Lifelong Learning Institute, a program designed for folks 50 and older.

This is about as interesting a topic as Ive ever taught for OLLI, said Evans, a former civil engineer as well as a local columnist and published author.

Sleep, he said, is the ultimate elephant in the room. Its vitally important but for something that takes up 25 or 30 years of a typical life its mostly ignored by our culture, except as a problem. For some, sleep is an enemy to be minimized, perhaps not realizing that adequate sleep is essential to our health and well-being. Others struggle with insomnia, worried theyre not getting enough sleep, popping pills or sedating themselves with alcohol. So, I wanted to give a balanced perspective, that is, an overview of the history, culture and neurology of sleep.

Sleep will cover a wide array of topics, including why people sleep and how much sleep one needs; sleep patterns of humans vs. other primates; sleep from a cultural and historical perspective; changing attitudes toward sleep; whats going on in peoples brains while theyre asleep; why people dream and do dreams mean anything; insomnia and how to deal with it; and the health dangers of getting too little sleep (with an emphasis on shift workers and school-age children).

Evans began studying sleep after learning that patterns today are quite different from years back.

I became fascinated with the topic when I first learned that our present sleep patterns are very different from those of our pre-artificial light forebears, he said. I was also shocked to learn how rapidly our sleep patterns are changing: 10 hours before the electric light (late 1800s), eight hours in 1950, 6.5 hours being the norm now.

To prepare for teaching the class, Evans read recent research on the neurology, health aspects and history of sleep in popular science books, Scientific American and other publications. He also watched YouTube lectures, scoured Google and Wikipedia and paid attention to his own sleeping patterns.

Im a world-class napper, Evans said, making up for my lack of nighttime sleep with daytime naps.

Sleep Perchance to Dream is taking place at the Humboldt Bay Aquatic Center in Eureka. The cost is $30 for Osher Lifelong Learning Institute members and $55 for non-members. To register, go to https://extended.humboldt.edu/olli.

More:
The subject of sleep - Eureka Times-Standard

Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND – GlobeNewswire

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five poster presentations at the 30th International Symposium on ALS/MND in Perth, Australia. The posters will be presented on Thursday, December 5, 2019 and Friday, December 6, 2019.

Thursday, December 5, 2019 (All times listed below are local time in Perth)

Poster Session ATheme: Clinical Trials and Trial Design

Title: Responder and Subgroup Analyses for FORTITUDE-ALS, a Phase 2 Trial Study of Reldesemtiv in Patients with ALSPresentation Time: 10:30 11:30 AMPoster Number: CLT-21Poster Presenter: Jeremy M. Shefner, M.D., Ph.D., Lead Investigator of FORTITUDE-ALS, Professor and Chair of Neurology at Barrow Neurological Institute, and Professor and Executive Chair of Neurology at the University of Arizona, Phoenix

Title: Quality of Life and Depression Measurements in FORTITUDE-ALSPresentation Time: 10:30 11:30 AMPoster Number: CLT-22Poster Presenter: Stacy Rudnicki, M.D., Senior Medical Director, Clinical Research, Neurology, Cytokinetics

Title: Impact of ALSFRS-R progression rates on outcome measures in FORTITUDE-ALS Presentation Time: 10:30 11:30 AMPoster Number: CLT-23Poster Presenter: Stacy Rudnicki, M.D., Senior Medical Director, Clinical Research, Neurology, Cytokinetics

Title: Utilization of Durable Medical Equipment in FORTITUDE-ALSPresentation Time: 10:30 11:30 AMPoster Number: CLT-20Poster Presenter: Stacy Rudnicki, M.D., Senior Medical Director, Clinical Research, Neurology, Cytokinetics

Friday, December 6, 2019

Poster Session BTheme: Biomedical and Clinical Work in Progress

Title: People Living with ALS and Their Caregivers Input into Drug Development in EuropePresentation Time: 6:00 7:00 PMPoster Number: WP-14Poster Presenter: Miriam Galvin, Ph.D., Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin

About Cytokinetics

Cytokineticsis a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.Cytokineticsis collaborating withAmgen Inc.(Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of an international clinical trials program in patients with heart failure including GALACTIC-HF and METEORIC-HF.Amgenholds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization inEuropeand certain other countries.Cytokineticsis collaborating withAstellas Pharma Inc.(Astellas) to develop reldesemtiv, a fast skeletal muscle troponin activator (FSTA). Astellas holds an exclusive worldwide license to develop and commercialize reldesemtiv. Licenses held byAmgenand Astellas are subject to specified co-development and co-commercialization rights ofCytokinetics.Cytokineticsis also developing CK-274, a novel cardiac myosin inhibitor that company scientists discovered independent of its collaborations, for the potential treatment of hypertrophic cardiomyopathies.Cytokineticscontinues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information aboutCytokinetics, visitwww.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics and its partners research and development activities; the Phase 2 clinical study of reldesemtiv in patients with ALS, including that such results may support progression of reldesemtiv into a potentially pivotal Phase 3 clinical trial; the potentially beneficial effects of reldesemtiv; and the properties and potential benefits of Cytokinetics other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics drug candidates that could slow or prevent clinical development or product approval; Astellas decisions with respect to the design, initiation, conduct, timing and continuation of development activities for reldesemtiv; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics business, investors should consult Cytokinetics filings with the Securities and Exchange Commission.

Contact:CytokineticsDiane WeiserVice President, Corporate Communications, Investor Relations(650) 624-3060

The rest is here:
Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND - GlobeNewswire

Neurologist in Asheville | Asheville Neurology Specialists

At Asheville Neurology, our Board Certified Neurologists Dr. Armstrong, Dr. Patton and Dr. Engelbrecht work with our Physician Assistants to ensure that we are providing quality, evidence based care to our patients and their loved ones. With a newly created Department of Patient Experience, we focus on quality improvement and patient feedback, which we then use to continuously improve. Our office environment is gentle and welcoming, and designed with our patients and their loved ones experiences in mind.

Our team based care approach begins the moment we receive a new referral, when we began to triage and make sure that we believe that the diagnosis is within the scope of our practice. Once the referral has been accepted, new patients receive a call from our scheduler. During this phone call, we make sure that our patients are aware of the resources available to them, including accessing our Patient Portal and pre-registering for their appointments. Because of our pre-registration process, we are able to get valuable updated clinical and demographic information prior to our patients appointment, which allows us to spend more time during the visit focusing on what you want to talk about.

Meet Our Team

More here:
Neurologist in Asheville | Asheville Neurology Specialists

Robert M. Cain, M.D. Adult and Pediatric Neurology

Dr. Cain is a Neurologist who has been in private practice since 1973 in Austin, Texas.He completed his medical degree in 1966 at the Ohio State University Medical School in Columbus, Ohio. During that time, he did a three-month internship with the Evangelical Presbyterian Church in Ghana, West Africa. Dr. Cain completed an internship in surgery at the George Washington University Hospital in Washington, DC. He then worked again in Africa for the Gulf Oil Corporation in Angola, Portuguese West Africa. He then returned to the Cleveland Clinic and did a fellowship in neurology at the Cleveland Clinic. He then left the Cleveland Clinic and did a years fellowship in pediatric neurology at the National Childrens Hospital in Washington, D.C. He then went to the Childrens Hospital in Boston, Massachusetts, Harvard Service under Dr. Cesare Lombroso in the seizure unit. Dr. Cain then established practice in Austin, Texas and has been in continuous practice since that time. He has vast experience in multiple sclerosis. He is a Board member of the Lone Star Chapter of the National Multiple Sclerosis Society. He was nominated for chairman.

MEMBERSHIPS -American Board of Psychiatry and Neurology, June 1977 -Texas Neurofibromatosis Foundation Past Board Member -American Academy of Neurology Active Member and Fellow -American Society of Neuroimaging Board Certified 1986 -Texas Neurologic Societies Founding Member -American Medical Association Member -Austin Neurologic Society Member -American Association for the Study of Headache Active Member -National Multiple Sclerosis, Lone Star Chapter Board Member -Nominated for Chairman -American Society of Neuroimaging Active Member -North American Spine

Click for downloadable version of Robert M. Cain CV

See the original post here:
Robert M. Cain, M.D. Adult and Pediatric Neurology

Neurology Grand Rounds – University of Oklahoma Health …

Venue: Samis Education Center Rainbolt Family Auditorium

Topic: Cerebrovascular Aging

Speakers:

Anna Csiszar, MD, PhD

Learning Objectives:

1. Identify major structural and functional differences between young and aged cerebrovasculature.

2. Recognize the mechanisms how aging of the brains vasculature can contribute to the development of cognitive impairment.

3. Apply new interventional strategies tailored for older populations.

Professional Practice Gap:

Current State: Neither dementia research (primarily Alzheimers Disease) nor stroke research could develop a major new drug target in the last 2 decades. One of the reasons is that the current research endeavors are focused on young preclinical models with intact function and repair capacity.Desired State: New models are needed to better understand the age-dependency and complexity of chronic, age-related diseases.

Speaker Disclosures:

None

For More Information Contact:

Brigitte NettlesNeurology Grand Rounds CoordinatorTel (405) 271-4113 Ext 46023E-mail: brigitte-nettles@ouhsc.edu

Number of CE Credits: 1

See the original post here:
Neurology Grand Rounds - University of Oklahoma Health ...

Neurology Times

Dec 06, 2017

A study found that patients with AF who initiate therapy with standard dose dabigatran are at low risk of stroke and bleeding. Insights here.

Dec 06, 2017

These medical apps provided technology for caregivers to track symptoms, make appointments with doctors, monitor medications, and more.

Dec 05, 2017

Higher fish intake was linked to significantly decreased rate of episodic memory decline. More details in this study.

Dec 05, 2017

The practice of forcing left-handers to use their right hand is a long as human history and found in most societies. In fact, the words left and left-handed are synonyms for defective or sinister in almost all the worlds languages. More in this interview.

Nov 29, 2017

Despite optimism, telemedicine has been only slowly adopted as a means of health care delivery. But things are changing. Have you considered adopting telemedicine in your clinic practice?

Nov 28, 2017

The highest level of comprehensive care targets youths with epilepsy who have known comorbid psychiatric, developmental, and cognitive disorders and/or a history of nonadherence to seizure medication.

Nov 28, 2017

What percentage of opioid overdose deaths in the US are linked to prescription opioids? This question and more in our quiz.

Nov 27, 2017

Is caffeine consumption associated with risk for Parkinson disease? Is there a short-term benefit to caffeine that is sustainable over the long term? These questions and more in this quiz.

Nov 27, 2017

Can treatment of subclinical hypothyroidism help diminish frequency and severity of migraines? This study suggests that levothyroxine can do both.

Nov 27, 2017

A study that compared motor and nonmotor outcomes of DBS for Parkinson disease may show promise for patients' quality of life.

Read more here:
Neurology Times

Blue Sky Neurology

Kirsten Bracht, M.D.

Board Certified in Neurology Fellowship Trained in Clinical Neurophysiology Special Interest in Clinical Neurophysiology, Sleep Medicine, and EpilepsyView More

Richard Clemmons, M.D.

Board Certified in Neurology, Epilepsy, and Advanced Central Clinical Neurophysiology (with added competency in Epilepsy Monitoring) Fellowship Trained in EEG and Epilepsy Special Interest in Epilepsy, Pediatric Epilepsy, EEG, and Epilepsy MonitoringView More

Aaron Haug, M.D.

Board Certified in Neurology Fellowship Trained in Movement DisordersDeep Brain Stimulation (DBS)View More

Beverly Gilder, M.D.

Board Certified in Neurology Fellowship Trained in Neuromuscular MedicineSpecial Interest in Multiple Sclerosis and MigrainesView More

Kimberly Horiuchi, M.D.

Board Certified in Neurology and Epilepsy Fellowship Trained in Epilepsy Special Interest in Seizures and EpilepsyView More

Judy Lane, M.D.

Board Certified in Headache Medicine and Neurology Residency in Neurology Special Interest in Migraine, Cluster Headache, Post-Traumatic Headache, and Head PainView More

Chuck Livsey, M.D., Ph.D.

Board Certified in Neurology and Epilepsy Fellowship Trained in Epilepsy Special Interest in EpilepsyView More

Bruce Morgenstern, M.D.

Board Certified in Neurology Fellowship Trained in Neuromuscular Disease andElectrophysiology Special Interest in Neuromuscular DiseaseView More

Ernest Nitka, M.D.

Joined our practice on October 1, 2015! Board Certified in Neurology Over 30 Years of Neurology ExperienceView More

Lyndsey Hale, M.D., M.P.H.

Joined our practice on August 17, 2015! Board Certified in Neurology Residency in NeurologyView More

Lisa Roeske-Anderson, M.D.

Board Certified in Neurology Fellowship Trained in Clinical Electrophysiology/EMG Special Interest in Concussion/Traumatic Brain InjuryView More

Michael Pearlman, M.D., Ph.D.

Board Eligible in Neurology Fellowship Trained in Neuro-Oncology Special Interest in Cancer NeurologyAdults and ChildrenView More

Jonathan Scott, M.D.

Board Certified in Neurology Fellowship Trained in Stroke Special Interest in Neurology and StrokeView More

Marc Y. Wasserman, M.D.

Board Certified in Neurology Fellowship Trained in Neurophysiology Special lnterest in migraine, seizure disorders, memory difficulties and general neurological conditionsView More

Alex Dietz, M.D.

Joins the Blue Sky Neurology Team in August 2017 Board Certified in Neurology Accepting patients at our Englewood locationView More

Nathan Kung, M.D.

Joins the Blue Sky Neurology Team in August 2017 Board Certified in Neurology Fellowship trained in Clinical Neurophysiology and Neuro-Ophthalmology Accepting patients at our Denver locationView More

Visit link:
Blue Sky Neurology

Neurology & Neurosurgery | Services | University Hospitals …

At University Hospitals, our team of nationally-recognized neurology and neurosurgery experts is committed to providing the highest quality care for patients with neurological disorders or injuries. Headed by University Hospitals Neurological Institute, our physicians combines cutting-edge research and innovative techniques to deliver comprehensive, personalized care for a wide range of conditions.

Learn more about this service at the following locations:

Learn more about this service at the following locations:

Learn more about this service at the following locations:

Learn more about this service at the following locations:

University Hospitals Epilepsy Center, part of the UH Neurological Institute, is recognized as one of the leading programs in the nation for diagnosis, treatment and research of the more than 30 types of epilepsy that affect adults and children. Patients are given personalized care and access to cutting-edge treatments to help control seizures and greatly improve their quality of life. Our expert researchers also work to develop new techniques surgical procedures to treat patients with epilepsy.

Learn more about this service at the following locations:

Learn more about this service at the following locations:

Learn more about this service at the following locations:

Learn more about this service at the following locations:

Learn more about this service at the following locations:

Learn more about this service at the following locations:

Learn more about this service at the following locations:

Learn more about this service at the following locations:

Learn more about this service at the following locations:

Learn more about this service at the following locations:

Learn more about this service at the following locations:

Learn more about this service at the following locations:

Learn more about this service at the following locations:

This service is also offered at the following locations:

Read more:
Neurology & Neurosurgery | Services | University Hospitals ...

Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: | JPR – Dove Medical Press

Alaa Elmazny, Sherif M Hamdy, Maged Abdel-Naseer, Nevin M Shalaby, Hatem S Shehata, Nirmeen A Kishk, Mona A Nada, Husam S Mourad, Mohamed I Hegazy, Ahmed Abdelalim, Sandra M Ahmed, Ghada Hatem, Amr M Fouad, Hadel Mahmoud, Amr Hassan

Neurology Department, Faculty of Medicine, Cairo University, Cairo, Egypt

Correspondence: Hatem S ShehataNeurology Department, Cairo University, 23 Amin Samy Street Kasr Alaini Street, Cairo, EgyptTel +2011124444179Fax +20227927795Email samirhatem@kasralainy.edu.eg

Background: Studies have shown that interferon-beta (IFN-) treatment is associated with headaches in patients with multiple sclerosis (MS). Headaches can affect quality of life and overall function of patients with MS. We examined the frequency, relationships, patterns, and characteristics of headaches in response to IFN- in patients with relapsing-remitting multiple sclerosis (RRMS).Patients and Methods: This study was a prospective, longitudinal analysis with 1-year follow-up. The study comprised 796 patients with RRMS treated with IFN- (mean age 30.84 8.98 years) at 5 tertiary referral center outpatient clinics in Egypt between January 2015 and December 2017. Headaches were diagnosed according to the International Classification of Headache Disorders ICHD-3 (beta version), and data were collected through an interviewer-administered Arabic-language-validated questionnaire with an addendum specifically designed to investigate the temporal relationship between commencement of interferon treatment, and headache onset and characteristics.Results: Twohundred seventy-six patients had pre-existing headaches, and 356 experienced de novo headaches. Of 122 patients who experienced headaches before IFN- treatment, 55 reported headaches that worsened following onset of IFN- treatment. In patients with post-IFN- headaches, 329 had headaches that persisted for > 3 months, 51 had chronic headaches, and 278 had episodic headaches, and 216 of these patients required preventive therapies. Univariate analysis showed a > 6- and an approximately 5-fold increased risk of headache among those treated with intramuscular (IM) INF--1a (OR 6.51; 95% CI: 3.73 10.01; P-value < 0.0001) and 44 g of SC INF--1a (OR 5.44; 95% CI: 3.15 9.37; P-value < 0.0001), respectively, compared with that in patients who received 22 g of SC INF--1a.Conclusion: Interferon- therapy aggravated pre-existing headaches and caused primary headaches in patients with MS. Headache risk was greater following treatment with IM INF--1a and 44 g SC INF--1a.

Keywords: headache, interferon-beta, multiple sclerosis

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continue reading here:
Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: | JPR - Dove Medical Press

Smartphone Use and Headache: What’s the Link? – Clinical Advisor

Increased smartphoneuse was found to be associated with an increased requirement of acutemedication and less relief from medication for primary headache, but not anincrease in frequency or duration of headaches, according to research publishedin Neurology Clinical Practice.

Smartphonetechnology is advancing at a rapid rate, but excessive engagement with thesedevices is raising health concerns. In a cross-sectional study, researcherssought to determine whether smartphone use was associated with worsening ofprimary headache, including migraine, chronic migraine, and tension-typeheadaches.

The study wasconducted between June 2017 and December 2018 in India, and included patients aged14 years with primary headache. All patients underwent detailed neurologicexamination and relevant investigations; information about headache pattern,severity, frequency, duration of episodes, character, location, and associatedcomplaints were noted. Information was also obtained about new-onset headachesof >3 months.

Each patient wasrequired to answer questions regarding mobile phone use with respect to type ofcell phone, daily usage duration, and type of usage. Questions were scored as 0for no and 1 for yes, with the highest score of thequestionnaire being 11. Patients were divided into non-smartphone users (NSUs; eitherdid not use a cell phone or non-smartphone user) and smartphone users (SUs).

The primary objective was to determine the association between mobile phone usage and new-onset headache or increases severity of primary headache. Chronic migraine was defined as headache for >15 days a month for >3 months. Worsening headache was defined as 2-fold increase in severity and/or intensity. Secondary outcomes included the association of smartphone use in patients with primary headache who required medication, as well as the dosage, type of analgesic taken, pill count of acute medications per month, number of prophylactic drugs, duration of prophylactic drug use, and dosage.

A total of 400patients were included in the study (194 NSU; 206 SU). Of the 194 NSU patients,76 were not using any phone and 130 were using non-smartphones. NSU patientswere older compared with SU patients. The majority of patients with headachewere women (269/400); however, more men were in the SU group compared with theNSU group (39.3% vs 25.8%).

The most commonheadache type was migraine, followed by chronic migraine and chronictension-type headache. More patients in the SU group reported more aurascompared with the NSU group (17.5% vs 7.7%), but the course of headache wassimilar in both groups (worsened: NSUs, 71.6% vs SUs, 71.8%).

Patients in the NSU grouphad similar duration of episodes compared with SU patients, as well as thenumber of episodes of headache per month (NSU, 7.3 vs SU, 7.1). Patients in theSU group took a higher number of pills for acute treatment with a median pillintake of 8 per month compared with 5 per month in the NSU group. A higherproportion of patients in the NSU group had relief with acute medicationscompared with the SU group, but the proportions of patients taking prophylacticmedication and the median duration of prophylaxis were similar in both groups.

Although thecourse of headache, frequency of episodes, and the pain scores were similar inNSUs and SUs, the SU group had higher frequency of medications for acuteattacks with poor response to analgesics, the authors concluded.

Reference

Uttarwar P, Vibha D, Prasad K, Srivastava AK, Pandit AK, Dwivedi SN. Smartphone use and primary headache: a cross-sectional hospital-based study Neurol Clin Pract. doi:10.1212/CPJ.0000000000000816

Read more:
Smartphone Use and Headache: What's the Link? - Clinical Advisor

Shared Genetic Variants Associated With Migraine and Multiple Sclerosis – Neurology Advisor

WEST PALM BEACH, FL Migraine prevalence was significantly higher among patients with multiple sclerosis (MS) compared with healthy controls, with several genetic variants being shared between migraine and MS, according to research presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2020 Forum held from February 27 to 29, 2020, in West Palm Beach, Florida. Several variants were found to increase migraine risk but decrease MS risk; these findings may lead to improvements in targeted treatments and therapies.

Although symptoms and risk factors for migraine and MS often overlap, and up to 69% of patients with MS suffer migraine, it is unknown whether these 2 disorders are independent or have a common biological etiology, such as genetics. The current study used data on 1094 patients with MS and 12,176 control participants who were Kaiser Permanente Northern California Health Plan members to investigate if any genetic variants independently associated with migraine or MS could be identified from genome-wide association studies that are shared between both conditions.

Migraine status was determined via self-report and validated electronic health record algorithm. Prior genome-wide association studies of MS or migraine were used to identify variants, and after quality control, investigators analyzed 902 variants with minor allele frequency greater than 1%. Observed and permuted P for each phenotype were obtained from logistic regression and compared with identify variants associated with both phenotypes. Logistic regression models were adjusted for sex and ancestry among any variants that had significant associations with both phenotypes.

The migraine model was adjusted for a propensity score representing the probability of MS case-control status to account for potential ascertainment bias from obtaining a secondary phenotype from a case-control study.

Among the 1094 patients with MS, the mean age was 49.95 years old (SD=9.02) compared with 49.01 years old (SD=8.92) for controls. Women made up 79.98% of MS cases and 80.60% of controls. Median MS Severity Score was 3.21 (SD=2.43). Migraine incidence was significantly higher (P <.05) among MS cases (40%) compared with controls (29%). Preliminary results found 5 genetic variants (rs6677309, rs10801908, rs1335532, rs62420820, and rs17066096) that were significantly associated (P <.05) with both MS and migraine. Three of these were protective for MS (rs6677309, rs10801908, and rs1335532), and all variants increased odds of migraine.

Study investigators concluded, Results showed the prevalence of migraine was significantly higher among individuals with MS compared [with] healthy controls.Several genetic variants were shared between MS and migraine, and implicated genes include CD58, which modulates regulatory T-cells, and several immune genes (IL20RA, IL22RA2, IFNGR1 and TNFAIP3) within the 6q23 chromosomal region. Because several variants increase risk of migraine but decrease risk of MS, there may be implications for targeted therapies and treatments.

Visit Neurology Advisors conference section for continuous coverage from the ACTRIMS 2020 Forum.

Reference

Horton M, Robinson S, Shao X, et al. Discovery of shared genetic variants associated with multiple sclerosis and migraine. Presented at: 5th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum; February 27-29, 2020; West Palm Beach, FL. Abstract P140.

Go here to see the original:
Shared Genetic Variants Associated With Migraine and Multiple Sclerosis - Neurology Advisor

Neurovascular or Interventional Neurology Devices Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast to 2026 – News Times

The report on the Neurovascular or Interventional Neurology Devices Market is a compilation of intelligent, broad research studies that will help players and stakeholders to make informed business decisions in future. It offers specific and reliable recommendations for players to better tackle challenges in the Neurovascular or Interventional Neurology Devices market. Furthermore, it comes out as a powerful resource providing up to date and verified information and data on various aspects of the Neurovascular or Interventional Neurology Devices market. Readers will be able to gain deeper understanding of the competitive landscape and its future scenarios, crucial dynamics, and leading segments of the Neurovascular or Interventional Neurology Devices market. Buyers of the report will have access to accurate PESTLE, SWOT, and other types of analysis on the Neurovascular or Interventional Neurology Devices market.

The Global Neurovascular or Interventional Neurology Devices Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2019 to 2026.

Key Players Mentioned in the Neurovascular or Interventional Neurology Devices Market Research Report:

Neurovascular or Interventional Neurology Devices Market: A Competitive Perspective

Competition is a major subject in any market research analysis. With the help of the competitive analysis provided in the report, players can easily study key strategies adopted by leading players of the Neurovascular or Interventional Neurology Devices market. They will also be able to plan counterstrategies to gain a competitive advantage in the Neurovascular or Interventional Neurology Devices market. Major as well as emerging players of the Neurovascular or Interventional Neurology Devices market are closely studied taking into consideration their market share, production, revenue, sales growth, gross margin, product portfolio, and other significant factors. This will help players to become familiar with the moves of their toughest competitors in the Neurovascular or Interventional Neurology Devices market.

Neurovascular or Interventional Neurology Devices Market: Drivers and Limitations

The report section explains the various drivers and controls that have shaped the global market. The detailed analysis of many market drivers enables readers to get a clear overview of the market, including the market environment, government policy, product innovation, development and market risks.

The research report also identifies the creative opportunities, challenges, and challenges of the Neurovascular or Interventional Neurology Devices market. The framework of the information will help the reader identify and plan strategies for the potential. Our obstacles, challenges and market challenges also help readers understand how the company can prevent this.

Neurovascular or Interventional Neurology Devices Market: Segment Analysis

The segmental analysis section of the report includes a thorough research study on key type and application segments of the Neurovascular or Interventional Neurology Devices market. All of the segments considered for the study are analyzed in quite some detail on the basis of market share, growth rate, recent developments, technology, and other critical factors. The segmental analysis provided in the report will help players to identify high-growth segments of the Neurovascular or Interventional Neurology Devices market and clearly understand their growth journey.

Ask for Discount @ https://www.marketresearchintellect.com/ask-for-discount/?rid=151352&utm_source=NT&utm_medium=888

Neurovascular or Interventional Neurology Devices Market: Regional Analysis

This section of the report contains detailed information on the market in different regions. Each region offers a different market size because each state has different government policies and other factors. The regions included in the report are North America, Europe, Asia Pacific, the Middle East and Africa. Information about the different regions helps the reader to better understand the global market.

Table of Content

1 Introduction of Neurovascular or Interventional Neurology Devices Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Market Research Intellect

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Neurovascular or Interventional Neurology Devices Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Neurovascular or Interventional Neurology Devices Market , By Deployment Model

5.1 Overview

6 Neurovascular or Interventional Neurology Devices Market , By Solution

6.1 Overview

7 Neurovascular or Interventional Neurology Devices Market , By Vertical

7.1 Overview

8 Neurovascular or Interventional Neurology Devices Market , By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Neurovascular or Interventional Neurology Devices Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Report Customization @ https://www.marketresearchintellect.com/product/global-neurovascular-or-interventional-neurology-devices-market-size-and-forecast/?utm_source=NT&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven FernandesMarket Research IntellectNew Jersey ( USA )Tel: +1-650-781-4080

Email: [emailprotected]

TAGS: Neurovascular or Interventional Neurology Devices Market Size, Neurovascular or Interventional Neurology Devices Market Growth, Neurovascular or Interventional Neurology Devices Market Forecast, Neurovascular or Interventional Neurology Devices Market Analysis, Neurovascular or Interventional Neurology Devices Market Trends, Neurovascular or Interventional Neurology Devices Market

View original post here:
Neurovascular or Interventional Neurology Devices Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast to 2026 - News Times